Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (DE:BM8)
FRANKFURT:BM8
RESEARCH TOOLSreports
Holding DE:BM8?
Track your performance easily
BM8 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€58.16 - €87.32
Previous CloseN/A
Volume0.00
Average Volume (3M)292.00
Market Cap
$12.53B
Enterprise Value€13.54B
Total Cash (Recent Filing)$789.68M
Total Debt (Recent Filing)$660.76M
Price to Earnings (P/E)39.9
Beta0.22
Next Earnings
Feb 20, 2025EPS Estimate
0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.66
Shares Outstanding190,583,020
10 Day Avg. Volume517
30 Day Avg. Volume292
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.66
Price to Cash Flow (P/CF)14.50
P/FCF Ratio16.00
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue4.92
Enterprise Value/Gross Profit7.11
Enterprise Value/Ebitda26.84
Forecast
1Y Price Target
€95.57Price Target Upside44.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering25
BioMarin Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBioMarin is seen as undervalued at current levels with a durable base business, leading to an Overweight rating being maintained.
Growth StrategyThe newly announced long-term strategy will aim to maximize commercial potential while improving operational efficiency, which should increase value for investors with shares being trading at five-year low.
Market PotentialThe significant untapped market for Voxzogo should support continued revenue growth, and its broad label allowing for early treatment initiation should help BioMarin to defend market dominance.
Bears Say
Competitive PressureThe convenience of TransCon CNP, which is a weekly subcutaneous injection, could be a key competitive advantage as compared to Voxzogo which is a daily subcutaneous injection.
Financial PerformanceThe company is below its guided compound annual growth rate ranges for 2026 and 2034.
Growth ConcernsThe apparent slowing of growth in Voxzogo, which is viewed as a 'make or break' franchise for BioMarin, could disappoint investors.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.95% Insiders
36.73% Mutual Funds
0.04% Other Institutional Investors
39.78% Public Companies and Individual Investors
BM8 FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was €58.16 and its highest was €87.32 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
BioMarin Pharmaceutical’s market cap is $12.53B.
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Feb 20, 2025 which is in 36 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Oct 29, 2024. The company reported €0.537 earnings per share for the quarter, beating the consensus estimate of €0.518 by €0.019.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is 0.53.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 190,583,020 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of €0.537 in its last earnings report, beating expectations of €0.518. Following the earnings report the stock price went down -3.65%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Currently, no hedge funds are holding shares in DE:BM8
---
BioMarin Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€95.57 (44.19% Upside)
€95.57 (44.19% Upside)
Blogger Sentiment
Bullish
DE:BM8 Sentiment 80%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $350.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.22%
12-Months-Change
Fundamentals
Return on Equity
6.25%
Trailing 12-Months
Asset Growth
1.38%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
---
BM8 Company Deck
---
BM8 Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
BioMarin's third quarter performance showed strong revenue growth and profitability expansion, supported by successful commercial execution and strategic initiatives. However, challenges in Roctavian revenue and increased competition in the achondroplasia market introduce some risks.Read More>---
BM8 Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
---
BM8 Stock 12 Month Forecast
Average Price Target
€95.57
▲(44.19% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Alnylam Pharma
―
Vertex Pharmaceuticals
―
Regeneron
―
Sarepta Therapeutics
―
Neurocrine
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering BM8
1 Year
1 Year Success Rate
22/45 ratings generated profit
1 Year Average Return
-2.19%
reiterated a buy rating yesterday
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 48.89% of your transactions generating a profit, with an average return of -2.19% per trade.
---